1. Collet JP, et al. Lancet 2009;373:309-17

2. Trial profile
Collet JP, et al. Lancet 2009;373:309-17

3. Baseline characteristics of patients according to CYP2C19*2 genotype
Collet JP, et al. Lancet 2009;373:309-17

4. Cumulative occurrence of cardiovascular death, non-fatal myocardial infarction, or urgent revascularisation during clopidogrel exposure
Collet JP, et al. Lancet 2009;373:309-17

5. Main eff ects of CYP2C19*2 gene variant on cardiovascular outcomes
Collet JP, et al. Lancet 2009;373:309-17

6. Cumulative Kaplan-Meier estimates of the rates of first cardiovascular event (death, non-fatal myocardial infarction, or urgent revascularisation) during the follow-up period (A) and from 6 months after clopidogrel initiation (B)
Collet JP, et al. Lancet 2009;373:309-17